Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Biotage in connection with RWK Bidco’s public tender
Mandate

Vinge advises Biotage in connection with RWK Bidco’s public tender

April 22, 2025 M&A

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.

Biotage is a global supplier and solutions partner to a wide range of customers within drug discovery and development and analytical testing. Headquartered in Sweden, Biotage operates globally serving over 80 countries. The company is listed on Nasdaq Stockholm. The offer values Biotage to approximately SEK 11,607 million based on the total number of ordinary shares in Biotage.

Vinge’s team mainly consists of Dain Hård Nevonen, Joel Magnusson, Benjamin Vafaeian, Lovisa Jonassen, Vilma Henricsson, David Olander and Emelie Schoning.

Related

Vinge advises Revivo Group on the acquisition of IdeaPaint

 Revivo Group is continuing its expansion in Finland through the acquisition of IdeaPaint Oy, a Tampere-based company specialising in industrial surface treatment.
September 21, 2026

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

 Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026